Chapter A7

ROLE OF MICROGLIA AND MACROPHAGES IN EAE

Gennadij Raivich and Richard Banati
Perinatal Brain Repair Centre, Dept Obstetrics and Gynaecology, Dept Anatomy, University College London, UK and Molecular Neuropsychiatry Laboratory, Department of Neuropathology, Charing Cross Hospital, Imperial College School of Medicine, London, UK

Abstract: Microglia and macrophages are related cell types that play an important role in the pathogenesis of MS and EAE. This chapter reviews the role of these cells in the normal brain and their contribution to inflammatory demyelinating disease, including their role in antigen presentation, co-stimulation, and production of cytokines and other inflammatory mediators.

Key words: experimental autoimmune encephalomyelitis, macrophages, microglia, inflammation, antigen presentation, perivascular, parenchymal, meningeal

The microglia, a brain-resident, non-neuronal cell and the blood-derived or haematogenous macrophage represent two related cell types involved in key events in the development of pathology in Multiple Sclerosis and its autoimmune animal model, the Experimental Allergic Encephalomyelitis. Microglia and macrophages fulfil a variety of different functions, but they are also recognized for their ability to act as a particularly fine sensor of brain pathology. Both cell types are rapidly activated and recruited to sites of infection, neurodegeneration, stroke, autoimmune inflammatory models such as EAE and its presumptive human counterpart, multiple sclerosis. Microglia and macrophages are stimulated by a variety of cytokines, neurotransmitters, modulators and putative neurotoxins, extracellular matrix molecules and proteases present in the inflamed central nervous system. Moreover, both cell types are plastic in their morphology and cellular identity. The presence of dying cells and cell debris will cause a transformation of phagocytic microglia into a detached, rounded and migratory or amoeba-like (amoeboid) macrophage (Streit et al., 1988; Bohatschek et al., 2001). This also works in reverse: surrounded by a CNS environment, non-phagocytic macrophages freshly recruited from the blood stream will gradually develop...
branched processes and transform into ramified microglia (Flugel et al., 2001, Bohatschek et al., 2001).

Activated microglia and macrophages synthesise a cornucopia of different cytokines, trophic factors, ECM components and neurotransmitter-like molecules that could exert a positive or damaging effect on the adjacent cells. They also interact with other cells of the immune system, particularly T-cells, which are recruited to the sites of CNS inflammation. Both in vitro and in vivo evidence also suggests that they may act as competent presenters of antigen, inducing and regulating the intensity of T-cell mediated inflammation and tissue injury. The aim of the current chapter will be to provide an overview on the different, related types of microglia and macrophages in the normal brain, describe their cellular and molecular response in EAE and multiple sclerosis and finally focus on their direct contribution to neuropathology in autoimmune demyelinating disease.

1. MICROGLIA AND MACROPHAGES IN THE NORMAL BRAIN

The normal central nervous system consists of several different non-neuronal cell populations that are related to monocytes and macrophages in the bone marrow and peripheral tissues, based on the presence of specific cellular differentiation markers such as the aMb2 integrin (CD11b/CD18), IgG receptors (CD16/CD32), IBA1 and so on. The brain microglia comprise the largest component, located inside the neural parenchyma. In the normal resting state, they are highly ramified cells, with extensive branches that can cover spaces of 30-50 μm in diameter. These resting microglia are territorial, in that their cell bodies or branches are rarely seen to adhere to one another, unlike white matter oligodendrocytes contacting one another like pearls on a string (Suzuki and Raisman, 1992) or protoplasmic astrocytes with extensive cell process to process contacts at astrocyte boundaries which allow the spread of intracellular ions and other small molecules from one astrocyte to the next (Nedergaard, 1994; Bushong, 2002).

The perivascular macrophages are located in between the blood vessel endothelia, occasional perithelial cells and the basal membrane that separates the blood vessel from the surrounding neural parenchyma, the Robin-Virchow space. Perivascular macrophages are typically slender elongated cells (elongated in the direction of the blood vessel axis) with broad but short processes that sometimes go around the blood vessel. Most perivascular macrophages are located around small to moderate blood vessels inside the central nervous system. Unlike the microglia, they do not show the elaborate
A7. Role of Microglia and Macrophages in EAE

ramified structure typical of resting microglia, which could be due to spatial constraints, but also to a molecular and cellular micro-environment, different from that of neural parenchyma. These differences also extend to molecular markers, such as MHC2, cyclo-oxygenase or scavenger receptors, found on normal perivascular macrophages but not in resting microglia (Linnehan et al., 1999), and the paucity of the aMb2 integrin (Angelov et al., 1992).

The meningeal macrophages, a third group, are large and rounded cells located between meningeal epithelial cells and the basal membranes surrounding glia limitans, the astroglial lining encasing neural parenchyma. Immunohistochemically, meningeal macrophages are more closely related to perivascular macrophages, macrophages in chorio-epithelial and ventricular epithelial tissue and less to the highly ramified, resting microglia inside neural parenchyma. On the whole, the basal membranes of vessels meninges, ventricular and chorioepithelium, mark an anatomical border between two brain macrophage subpopulations: the ramified microglia inside the neural parenchyma that lacks intrinsic basal membranes, and perivascular, meningeal, ventricular or chorioepithelial cells sitting on the external side of the surrounding basal membranes.

Some publications also use the term “perivascular microglia”, but the term is confusing, controversially defined, and frequently misleading. It is often used as a synonym for rounded or process-poor perivascular macrophages (Linnehan et al., 1999; Stoll and Jander, 1999), even though these cells look very different from the ramified microglia. In others, it is used to denote microglia in the neural parenchyma with processes that contact blood vessels from the inside (Owens et al., 1998). Since each microglial cell covers a relatively large territory of well vascularized tissue, up to 50-70 μm in diameter, some contact is probably unavoidable, and labelling a microglial cell “perivascular”, like that shown in figure 1C can simply reflect a particularly prominent process attached to a vessel co-stained by the same molecular marker.

Despite this clear anatomical partition, between microglia and macrophages, there is clearly at least some exchange between and plasticity in the individual compartments. Perivascular macrophages are gradually replenished by a pool of circulating monocytes, with a half-life of 1-2 months. A small population of macrophages migrate through basal membrane into neural parenchyma, to differentiate into ramified microglia, a process enhanced in different forms of neuropathology (Streit et al., 1989; Priller et al., 2001), including EAE (Fluegel et al., 2001). Resident microglia in the adult brain are themselves descendents of 2 waves of macrophage infiltration into neural parenchyma – a very early one, from the surrounding mesodermal tissue (Navascues et al., 1995; Cossmann et al., 1997; Kurz and Christ, 1998), then as a second wave, as “fountains of microglia” in CNS white matter during axonal pruning in the late fetus/newborn (Rio-Hortega cf Brockhaus et al., 1996), but this is followed by rapid differentiation,
arborisation and quiescence, turning into the resting, ramified phenotype. However, the same resident microglia can be rapidly activated by a host of different pathologies, lose branching and transform into amoeboid macrophages. Some debris-laden transformed microglia also appear to migrate from neural parenchyma into the perivascular, Robin-Virchow space, where they can stay for a very long time (Kosel et al., 1997), which could set the scene for an interaction with T-cells homing onto perivascular macrophages (Walter et al., 2001).

2. CELLULAR AND MOLECULAR RESPONSE IN EAE AND MS

The rapid recruitment of blood-borne monocytes, the activation of resident microglia and perivascular macrophages, together with the recruitment of T-cells, are among the most consistent changes observed in multiple sclerosis and its autoimmune animal models of experimental allergic encephalomyelitis (McCombe et al., 1994; Bruck et al., 1995; Ford et al., 1995; Li et al., 1996). Microglia display strong proliferative activity, particularly at the early active sites of demyelination (Matsumoto et al., 1992, Schonrock et al., 1998), and avid upregulation in their mitogen receptors, that is tuned down in later stages of the disease (Hulkower et al., 1993; Werner et al., 2002). Compared to neighbouring T-cells, microglia/macrophages show relatively little apoptosis (Nguyen et al., 1994; Smith et al., 1996; Bonetti et al., 1997) and much more proliferative activity (Ogmori et al., 1992). Interestingly, almost all of our knowledge of changes affecting brain microglia/macrophages in the human disease come from the post mortem analysis of the terminal stage, unlike the EAE models which allow to explore pathology at different phases of the disease - from the early preclinical stage, to onset of neurological symptoms, paralysis and remission, including the second and following bouts of the disease process in the relapsing forms of the EAE.

Recent increase in the use of diagnostic brain biopsies (Bruck et al., 1995; Lucchinetti et al., 2000), but particularly the introduction of the positron-emitting $[^{11}C]$-PK11195 in combination with positron emission tomography (PET) scanning has begun to change this situation. In brain tissue, the PK1195 binding site is highly selective for microglia and macrophages, it is rapidly activated in even in moderate forms of brain pathology (Stephenson et al., 1995; Banati et al., 1997) and can be used map the spatial pattern of microglial activation in multiple sclerosis (Banati et al., 1999; Cagnin et al., 2001). Compared with magnetic resonance imaging with or without Gadolinium, the PET-based technique shows a higher sensitivity with respect to identifying white mater regions at risk and provides a good
correlation with disease process and appearance of neurological deficit (Banati et al., 2000). These recent human data underscore the importance of brain macrophage activation as a diagnostic tool, to identify the localization and disease activity in multiple sclerosis.

Figure 1. Detection of microglial activation in human patients with multiple sclerosis using positron emission tomography (PET) with [11C](R)-PK11195, combined with nuclear magnetic resonance imaging (MRI). All images follow the radiological convention, i.e. the left side of the image corresponds to subject's right side. (A) Three orthogonal views of
On the biochemical level, macrophage and microglial activity in MS and EAE is associated with a strong upregulation of molecules involved in antigen presentation, myelin and tissue breakdown, production of reactive oxygen substances. They also synthesize components of the complement cascade, cytokines, growth factors and neurotrophins, chemotactic molecules, excitotoxins and apoptosis-inducing substances, and their receptors. These molecules, reviewed in the following paragraphs, as well as in more detail in the preceding and following chapters of this book, are involved in inducing and regulating the level of macrophage activation, interaction with encephalitogenic lymphocytes, mediating damage to myelin, axons and oligodendrocytes, as well as inducing the repair of the injured white matter.

ANTIGEN PRESENTATION

**Major Histocompatibility Complex.** T cells are known to recognize their specific antigen when associated to the class I or class II molecules of the major histocompatibility complex, abbreviated as MHC1 and MHC2 (for a review see Zinkernagel and Doherty, 1997). This recognition is aided by the binding of T-cell accessory molecules CD4 and CD8, expressed by the T-helper (mainly CD4+) and the T-suppressor/cytotoxic (mainly CD8+) lymphocytes, to their respective MHC2 or MHC1 ligands (Fleury et al., 1991; Miceli and Parnes, 1991). Despite the strong MHC class-selectiveness in the presentation of specific antigen – MHC1 for the endogenous (cytoplasmic) and MHC2 for the exogenous (phagocytosed) antigen, recent studies point to the existence of alternative and highly effective pathways for the presentation of exogenous antigen via MHC1 (Reimann et al., 1994;
Larsson et al., 2001). In addition, non-classical MHC1-like molecules such as CD1 can also present antigen, particularly glycolipids, to the CD8+ as well as to the CD4-CD8- (double null) T-lymphocytes (Sugita et al., 1998).

The rapid upregulation in the major histocompatibility complex antigens were amongst the first set of molecular changes described in multiple sclerosis as well as in different forms of experimental allergic encephalomyelitis using immunohistochemical techniques. Here, the upregulation of MHC2 was clearly restricted to reactive microglia, macrophages and blood-borne leukocytes, neighbouring GFAP+ astrocytes were MHC2 negative (Konno et al., 1989; Boyle and McGeer, 1990). Unlike MHC2, CD1 expression was not found on parenchymal macrophages or microglia, but rather on perivascular leukocytes and particularly, on the GMCSF+, hypertrophic astrocytes surrounding MS plaques (Battistini et al., 1996). Interestingly, the absence of overlap between MHC2 and CD1b suggests a high level of cell type selectivity in the presentation of MHC2 and CD1b-dependent antigens (Cipriani et al., 2003).

Up to now, most reports on antigen presentation and EAE have concentrated on MHC2, leading to the common assumption that only CD4+ lymphocytes are encephalitogenic. However, studies using beta2-microglobulin-deficient mice do show that MHC1 is involved in mediating EAE elicited by adoptively transferred, encephalitogenic CD8+ T-cells (Sun et al., 2001). This effect is direct and not mediated by some indirectly stimulated host CD4+ lymphocytes, a point demonstrated using the RAG 1/-, immunodeficient mice (Sun et al., 2001). In the majority of cases, antigen presentation by CD1+ cells appears to inhibit EAE (Lider et al., 2001; Miyamoto et al., 2001), although this depends on the cytokine requirements of the specific form of EAE (Jahng et al., 2001). In the case of MHC2, most initial reports tended to emphasize that microglial expression of MHC2 may present antigen to encephalitogenic T-cells, needed to initiate or promote the inflammatory and demyelinating process (Hayes et al., 1987; McGeer et al., 1988). More recent studies have focused on their counter-regulatory and immunosuppressive properties. EAE-inducing effects are now attributed to perivascular macrophages.

Studies by Hickey and Kimura using bone marrow chimaeras clearly show that MHC2 expression by perivascular macrophages is sufficient for antigen presentation and onset of severe EAE, following the transfer of encephalitogenic CD4+ T-cells (Hickey and Kimura, 1988). On the other hand, high level of microglial MHC2 corresponds with resistance to EAE in different strains of rats (Sedgwick et al., 1993; Klyushenkova et al., 1997). Exposure to microglial MHC2 also appears to induce T cell apoptosis, unlike the perivascular macrophages that promote T-cell survival (Ford et al., 1996; Klyushenkova et al., 1997). Presentation of antigen to non-encephalitogenic T-cells appears to play an important part in preventing excessive autoimmunity. Thus, adoptive transfer of encephalitogenic T-cells in mice
with severe combined autoimmunity (scid) leads to a much more severe and recurrent form of EAE compared with immunocompetent mice (Jones et al., 1999). The particularly strong and profuse upregulation of MHC2 on parenchymal microglia during early remission (Konno et al., 1989; McCombe et al., 1992) thus appears to make an important contribution in strengthening the immunosuppressive action of microglial MHC2.

**Accessory Molecules.** In addition to processed antigen embedded in MHC, effective antigen presentation requires the presence of co-stimulatory or accessory molecules on the surface of the antigen presenting cell, engaging their receptor counterparts on the T-lymphocyte. These accessory molecules belong to several different families of cell surface glycoproteins including B7, CD40, ICAM1-3 and the αβ2 integrin. αβ2 is a cell type-specific marker of professional, antigen-presenting cells (APC) also known as dendritic cells (Brocker et al., 1997; Suter et al., 2000).

MS is associated with a strong upregulation of CD40 (Gerritse et al., 1996; Laman et al., 1998; Weinberg et al., 1999) and B7.1 on the perivascular macrophages and microglia (Williams et al., 1994; De Simone et al., 1995). Inhibition or neutralization of CD40 and B7.1 prevented induction of EAE (Kuchroo et al., 1995; Gerritse et al., 1995; Weinberg et al., 1999; Becher et al., 2001). In the case of B7.1 this effect depended on the presence of IL4 (Kuchroo et al., 1995). Resting microglia already express moderate levels of B7.2 (Dangond et al., 1997), and its inhibition may enhance the severity of EAE (Kuchroo et al., 1995). Interestingly, combined inactivation of B7.1 and B7.2 strongly reduced the pathology and severity of neurological symptoms in adoptively transferred EAE (Chang et al., 1999). Both systems, CD40 and B7, appear to complement each other. Combined inactivation of the B7 receptor CD28, and inhibition of CD40 leads to a particularly strong resistance to the induction of EAE (Grivin et al., 2002).

Activated and phagocytic brain-resident microglia do express co-stimulatory molecules such as ICAM1-3, αβ2 or B7.2 in a variety of pathological conditions (Bo et al., 1996; Werner et al., 1998, Bohatschek et al., 1999; Kloss et al., 1999). However, most studies concur that the majority of the accessory molecule-positive cells in MS and EAE that present antigen to T-lymphocytes are hematogenous in origin and concentrated in the perivascular infiltrates (Williams et al., 1994; De Simone et al., 1995; Gerritse et al., 1996; Laman et al., 1998; Weinberg et al., 1999). Adoptive transfer of encephalitogenic T-cells strongly enhances the influx of bone marrow-precursors of dendritic cells to the site of CNS inflammation. Moreover, these newly recruited dendritic cells, with the appropriate MHC molecules, are fully sufficient to induce inflammation and myelin destruction in mice following adoptive transfer of rat bone marrow and rat encephalitogenic T-cells (Subramanian et al., 2001). This point is also
underscored by recent study using bone marrow chimaeras between the CD40 wild type (CD40+/+) and CD40 null (CD40-/-) animals, with the latter normally resistant to EAE (Becher et al., 2001). Replacement of the CD40+/+ bone marrow with that from a CD40-/- animal, turning perivascular macrophages and newly recruited dendritic cells to CD40-/-, while retaining CD40+/+ microglia, prevents the appearance of EAE in almost all animals. On the other hand, the transfer of CD40+/+ bone marrow to the irradiated, CD40-/- host, causes an almost complete recovery of EAE susceptibility in the host, with just a minor delay (+20%) and reduction in the maximal severity of clinical symptoms (-25%), compared to normal, CD40+/+ animals receiving a CD40+/+ bone marrow transplant (Becher et al., 2001).

**CYTOKINES**

Perivascular cuff macrophages, parenchymal macrophages and microglia show a strong upregulation for a long list of inflammation-associated, soluble cytokines, including interleukin-1/IL1 (Bauer et al., 1993), interleukin-10/IL10 (Jander et al., 1998; Hulshoff et al., 2002), transforming growth factor beta-1 (Kiefer et al., 1998; De Groot et al., 1999), macrophage-colony stimulating factor/MCSF (Hulkower et al., 1993; Werner et al., 2002), granulocyte-macrophage colony-stimulating factor (GMCSF), interleukin-12 (IL12) and tumour necrosis factor-alpha/TNFa (Hulkower et al., 1993; Renno et al., 1995; Bitsch et al., 1998; Laman et al., 1998; Fischer and Reichmann, 2001). There is also an upregulation of related cell surface molecules such as FAS and FAS-ligand (FasL), which are members of the TNF superfamily (Ouallet et al., 1999). Interestingly, expression is frequently focused to specific and different subpopulations of macrophages and microglia (Bitsch et al., 2000; Juedes et al., 2000). For example, the aMb2-positive microglia/macrophages expressing the dendritic cell marker aXb2 integrin secrete high amounts of IL12, while those negative for aXb2 produce GMCSF and TNFa (Fischer and Reichmann, 2001).

A subpopulation of these macrophage-produced cytokines and related molecules, such as IL10, TGFb1, or FasL has been shown to inhibit or prevent EAE (Rott et al., 19994; Stevens et al., 1994; Zhu et al., 2002; see also Wyss-Coray et al., 1997). However, a majority have a strong disease-promoting activity (Waldburger et al., 1996; Taupin et al., 1997; Marusic et l., 2002). Neutralization of TNF-alpha (Selmaj et al., 1991; Komer et al., 1997), IL1 (Jacobs et al., 1991), IL12 (Leonard et al., 1995) with antibodies or soluble receptors suppresses EAE. Genetic deletion of IL1R1, GMCSF, TNFa or IL12p40 has a similar effect, conferring resistance to EAE (Schaffenbauer et al., 2000; McQualter et al., 2001; Matejuk et al., 2002; Murphy et al., 2002; Gran et al., 2002; see however Liu et al., 1998).
Moreover, studies using bone marrow chimaeras between TNFa+/+ and TNFa-/- mice show that it is the TNFa which is produced by blood-borne leukocytes that plays a decisive role in the onset and severity of EAE (Murphy et al., 2002).

Importantly, moderate overexpression of TNFa or IL12, using the astrocyte GFAP promoter (Stalder et al., 1998; Pagenstecher et al., 2000) has been shown to lead to CNS inflammation and neurological disease. In the case of TNF, it causes overt demyelination and axonal damage very similar to that observed in EAE and MS. The fact that this demyelination is also observed in TNFa-overexpressing scid mice lacking T and B-cells (Stalder et al., 1998) strongly suggests that these cytokines not only promote the initial immune response, but also appear to play a crucial in the final steps following antigen recognition, that actually cause the brain pathology and neurological dysfunction.

CHEMOKINES

The activated macrophages and microglia produce a variety of chemotactic molecules including members of the chemokine family, but also many other chemoattractant factors such as secretoneurin (Storch et al., 1996), leukocyte chemotactic factor/LCF (Schluesener et al., 1996), endothelial-monocyte-activating polypeptide II (Schluesener et al., 1997) and chemotactic peptide-10/CP10 (Deininger et al., 1999). Amongst the chemokines, there is a strong increase in the macrophage chemotactic protein/MCP1 (Hulkower et al., 1993; Simpson et al., 1998, Jee et al., 2001), monocyte inflammatory protein 1 alpha/MIP1a (Balashov et al., 1999), neurotactin or fractalkine/CX3CL1 (Pan et al., 1997), TCA3 (Murphy et al., 2002), CCL19 and the macrophage-derived chemokine/CCL22 (Columba-Cabezas et al., 2002, 2003), which act as chemotactic ligands for macrophages, T-lymphocytes or both. There is also an upregulation for a list of macrophage chemokine receptors, such as CCR1, the receptor for MIP1a (Rottman et al., 2000; Trebst et al., 2001), CCR2, CCR3 and CCR5 (Simpson et al., 2000), CCR8 (Trebst et al., 2003), CXCR4 and CX3CR1 (Jiang et al., 1998), and the receptors for IL8 and N-formyl-Met-Leu-Phe/FMLP, particularly on foamy, phagocytic macrophages (Muller-Ladner et al., 1996).

Many of these macrophage-derived chemokines are produced by hematogenous macrophages, invading the inflamed CNS (Miyagishi et al., 1997; Sorensen et al., 1999; Matejuk et al., 2002) and are controlled by inflammation–associated cytokines such as TNF (Matejuk et al., 2002; Murphy et al., 2002). Studies using genetically deficient animals and/or neutralizing antibodies also show that the chemoattractive molecules play an important role in the pathology of EAE. Transgenic deletion of CCR1, the receptor for MIP1a, CCR2, the receptor for MCP1, or CCR8, the receptor
for TCA3, strongly reduce the susceptibility, onset and severity of EAE (Rottman et al., 2000; Huang et al., 2001; Murphy et al., 2002). A similar inhibitory effect is also observed with the antibody inactivation of MCP1 (Karpus et al., 1995). That these molecules are produced in the brain has suggested that brain-resident cells, particularly microglia, may also play a role in the induction of EAE (Murphy et al., 2002). However, this point is contentious and needs to be confirmed, using bone marrow chimaeras. The fact that many of these chemokines and chemokine receptors are located on blood-borne macrophages, particularly in perivascular cuffs, could argue against a major contribution by microglia.

**REACTIVE OXYGEN SPECIES AND SIGNALLING ENZYMES**

Acute inflammatory diseases such as EAE and multiple sclerosis are associated with strongly augmented production of reactive oxygen species (ROS), particularly by activated brain macrophages (Ruuls et al., 1995). Brain macrophages show increased deposition of iron (LeVine, 1997), myeloperoxidase (Nagra et al., 1997) and inducible NO synthase/iNOS in multiple sclerosis (Bagasra et al., 1995; De Groot et al., 1997) and in EAE (Van Dam et al., 1995; Tran et al., 1997). Similar upregulation is also observed in viral models of CNS demyelination, e.g. with Theiler’s murine encephalomyelitis virus (Oleszak et al., 1997). In combination with peroxide radicals the synthesis of NO will lead to the formation of peroxynitrite, which is toxic for oligodendrocytes (Mitrosic et al., 1996). In vitro, oxidative stress causes macrophages to become toxic (Bartnik et al., 2000), and scavengers of ROS or their precursors such as uric acid or catalase are known to inhibit EAE (Ruuls et al., 1995; Kean et al., 2000).

Nonetheless, brain macrophages also produce a string of molecules that reduce oxidative stress. Perivascular macrophages, and to lesser extent microglia, show high levels manganese superoxide dismutase in EAE (Qi et al., 1997). Expression of metallothioneins 1&2/MT1&2 (Espejo et al., 2001) reduces the high susceptibility to EAE, shown in the MT1&2/-/- mice (Penkowa et al., 2001). Multiple sclerosis and EAE also cause increased macrophage synthesis of stress protein heme oxygenase-1 (HO1) that produces CO (Emerson and LeVine, 2000; Schluesener and Seid, 2000), the inducer of cGMP-synthesizing enzyme guanyl cyclase (Brune and Ullrich, 1987). This increased HO1 degrades the pro-oxidant heme groups, but also reduces the availability of the NADPH cytochrome P450 reductase that is needed for the production of superoxide (Emerson and LeVine, 2000). Inducers of HO1 such as hemin, reduce the severity, and HO1 inhibitors enhance the severity of EAE (Liu et al., 2001).

Macrophage iNOS and NO synthesis and their effects in EAE have been a focus of particular attention. In most cases, early pharmacological inhibition of nitric oxide synthase has been shown to reduce EAE (Cross et
Late application interferes with the recovery process and enhances relapsing activity (Okuda et al., 1998; O’Brien et al., 2001). Interestingly, NO production by brain microglia and macrophages strongly inhibits T-cell proliferation (Juedes and Ruddle, 2001).

The importance of this point was illustrated by studies in the interferon gamma receptor deficient (IFNgR-/−) mice, that are normally unable to recover following the induction of EAE, and die from severe demyelinating illness (Willenborg et al., 1999). In vitro analysis showed that supernatants from IFNgR+/+ macrophages inhibit the proliferation of encephalitogenic T-cells while IFNgR-/− macrophages lack this ability. Moreover, the inhibitory effects of IFNgR+/+ macrophages could be suppressed by an inhibitor of iNOS, underscoring the importance of NO in regulating the T-cell response. Interestingly, bone marrow chimaeras between IFNgR+/+ and IFNgR-/− show that the presence of IFNg receptors on just one, blood-borne or brain resident component, was sufficient to prevent the normally lethal outcome following the induction of EAE in IFNgR-/− mice (Willenborg et al., 1999).

FUNCTIONAL ROLE

Both brain–derived microglia and blood borne macrophages are crucially involved in many consecutive stages of autoimmune demyelination in experimental allergic encephalomyelitis and multiple sclerosis. They play an important role as antigen-presenting cells in the initial demonstration of antigen (Hickey and Kimura, 1988; Jones et al., 1999), and secondary recruitment of T-cells, granulocytes and macrophages (Huitinga et al., 1995). They also produce a long list of potentially damaging substances, including reactive oxygen species, NO and peroxynitrite, TNFa, interleukin-1b and excitotoxins (see above). As a case in point, interleukin 1b has been shown to activate mixed glial cell cultures to produce glutamate agonist neurotoxins that cause oligodendroglial cell death (Takahashi et al., 2003). MS-associated inflammation leads to a strong increase in glutamate receptors on axons in the centre of CNS lesions and on neighboring, reactive astrocytes (Geurts et al., 2003), which could predispose them to damage by the gliadervived excitotoxins. Axonal damage is particularly intense at early disease stages of MS (Kuhlmann et al., 2002), which could correspond to particularly intense microglial activation (Bitsch et al., 2002). Microglia and macrophages are also the chief debris-removing cells that eliminate damaged myelin, resulting in the widespread loss of axonal covering the CNS white matter. Last, but not least, microglia and macrophages appear to play a decisive role in the induction of remission, as well as resistance to the induction of the disease (Konno et al., 1989; McCombe et al., 1992; Willenborg et al., 1999).
A key question raised with respect to microglia and macrophages is the relative contribution of blood-derived versus brain resident cell populations to the overall pathology during the process of autoimmune destruction of myelin. This question is particularly appropriate, since activated, and particularly phagocytic microglia share most of molecular markers with the blood-born macrophages that enter the damaged brain (Streit et al., 1988; Bruck et al., 1995; Raivich et al., 1999). Most studies concur that blood-derived macrophages are crucial in the induction of EAE. Removal of bone marrow monocyte precursors and circulating macrophages with clodronate reduces the parenchymal influx of new macrophages, interferes with lymphocyte recruitment and microglial proliferation (Bauer et al., 1995; Plofriet et al., 2002). The same macrophage depleting treatment also blocks adoptively transferred EAE (Huitinga et al., 1995; Tran et al., 1998). Similar, disease-abolishing results were also obtained in bone marrow chimaeras, when bone marrow-derived macrophages (but not microglia) lacked the appropriate MHC antigens, accessory molecules (CD40) or cytokines such as TNFα that promote demyelinating disease (Hickey and Kimura, 1988; Stalder et al., 1998; Subramanian et al., 2001; Becher et al., 2001; Murphy et al., 2002), underscoring the significance of blood derived macrophages.

Nonetheless, there are several lines of evidence that begin to shed light on the importance of brain resident microglia at different stages of the demyelinating disease. The initiation of the autoimmune response is an important case in point. For example, the acute transfer of rat encephalitogenic T-lymphocytes and appropriate antigen presenting cells (APC) to scid mice causes a delay phase of approximately 8 days before the onset of EAE (Subramanian et al., 2001), pointing to the importance of local APC in the early initial stages. This point is underscored by the very rapid microglial response to the adoptive transfer of EAE, in this case the induction of microglial amyloid precursor protein, within 24 hours after the infusion of encephalitogenic T-cells in animals with the appropriate MHC antigens (Banati et al., 1995). Studies using bone marrow chimaeras also show that microglia are much more effective removers of myelin than blood-derived macrophages (Rinner et al., 1995). Finally, brain-resident microglia also play a decisive role in limiting the extent of demyelination, preventing lethal outcome and inducing disease remission (Konno et al., 1989; McCombe et al., 1992; Willenborg et al., 1999). Here, new insights into the function and molecular signals of macrophages and microglia, their interaction with each other, as well as with T-lymphocytes, axons and myelin-producing oligodendroglia, could pave the way to introducing new and more effective therapies to the human demyelinating disease.
REFERENCES

Angelov DN, Neiss WF, Streppel M, Walther M, Guntinas-Lichius O, Stennert E (1996) ED2-positive perivascular cells act as neuronophages during delayed neuronal loss in the facial nucleus of the rat. Glia 16:129-39

Bagasra O, Michaels FH, Zheng YM, Bobroski LE, Spitsin SV, Fu ZF, Tawadros R, Koprowski H. 1995 Activation of the inducible form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc Natl Acad Sci USA 92:12041-5

Balashov KE, Rottman JB, Weiner HL, Hancock WW. 1999 CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci USA. 96:6873-8

Banati RB, Gehrmann J, Lannes-Vieira J, Wekerle H, Kreutzberg GW. (1995) Inflammatory reaction in experimental autoimmune encephalomyelitis (EAE) is accompanied by a microglial expression of the beta A4-amyloid precursor protein (APP). Glia 14:209-15

Banati RB, Myers R, Kreutzberg GW (1997) PK ('peripheral benzodiazepine')--binding sites in the CNS indicate early and discrete brain lesions: microautoradiographic detection of [3H]PK11195 binding to activated microglia. J Neurocytol 26:77-82

Banati RB, Goerres GW, Myers R, Gunn RN, Turkheimer FE, Kreutzberg GW, Brooks DJ, Jones T, Duncan JS (1999) [11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen's encephalitis. Neurology. 53:2199-203

Banati RB, Newcombe J, Gunn RN, Cagnin A, Turkheimer F, Heppner F, Price G, Wegner F, Giovannoni G, Miller DH, Smith T, Hewson AK, Bydder G, Kreutzberg GW, Jones T, Cuzner ML, Myers R (2000) The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 123:2321-37

Bartnik BL, Juurlink BH, Devon RM. 2000 Macrophages: their myelinotrophic or neurotoxic actions depend upon tissue oxidative stress. Mult Scler. Feb;6(1):37-42

Battistini L, Fischer FR, Raine CS, Brosnan CF. 1996 CD1b is expressed in multiple sclerosis lesions. J Neuroimmunol. 67(2):145-151.

Bauer J, Berkenbosch F, Van Dam AM, Dijkstra CD. 1993 Demonstration of interleukin-1 beta in Lewis rat brain during experimental allergic encephalomyelitis by immunocytochemistry at the light and ultrastructural level. J Neuroimmunol 48:13-21

Bauer J, Huitinga I, Zhao W, Lassmann H, Hickey WF, Dijkstra CD (1995) The role of macrophages, perivascular cells, and microglial cells in the pathogenesis of experimental autoimmune encephalomyelitis. Glia 15:437-46

Becher B, Durell BG, Miga AV, Hickey WF, Noelle RJ. 2001 The clinical course of experimental autoimmune encephalomyelitis and inflammation is controlled by the expression of CD40 within the central nervous system. J Exp Med. 193:967-74

Bitsch A, da Costa C, Bunkowski S, Weber F, Rieckmann P, Bruck W 1998 Identification of macrophage populations expressing tumor necrosis factor-alpha mRNA in acute multiple sclerosis. Acta Neuropathol (Berl). 95:373-7

Bitsch A, Kuhlmann T, Da Costa C, Bunkowski S, Polak T, Bruck W (2000) Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions: correlation with demyelinating activity and oligodendrocyte pathology. Glia. 29:366-75

Bo L, Peterson JW, Mork S, Hoffman PA, Gallatin WM, Ransohoff RM, Trapp BD (1996) Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions. J Neuropathol Exp Neurol. 55:1060-72.

Bonetti B, Pohl J, Gao YL, Raine CS 1997 Cell death during autoimmune demyelination: effector but not target cells are eliminated by apoptosis. J Immunol. 159:5733-41
A7. Role of Microglia and Macrophages in EAE

Boyle EA, McGeer PL. Cellular immune response in multiple sclerosis plaques. Am J Pathol 1990 Sep 137:575-84

Brenner T, Brocke S, Szafer F, Sobel RA, Parkinson JF, Perez DH, Steinman L. 1997 Inhibition of nitric oxide synthase for treatment of experimental autoimmune encephalomyelitis. J Immunol. 158:2940-6

Brocker T, Riedinger M, Karjalainen K (1997) Targeted expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo. J Exp.Med. 185 541-550.

Brockhaus J, Moller T, Kettenmann H (1996) Phagocytozing ameboid microglial cells studied in a mouse corpus callosum slice preparation. Glia 16:81-90

Bruck W, Porada P, Poser S, Rieckmann P, Hanefeld F, Kretzschmar HA, Lassmann H. 1995 Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol. 38:788-96

Bruck W, Porada P, Poser S, Rieckmann P, Hanefeld F, Kretzschmar HA, Lassmann H. 1995 Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol. 38(5):788-96

Brune B, Ullrich V (1987) Inhibition of platelet aggregation by carbon monoxide is mediated by activation of guanylate cyclase. Mol Pharmacol. 32:497-504

Bushong EA, Martone ME, Jones YZ, Ellisman MH. 2002 Protoplasmic astrocytes in CA1 stratum radiatum occupy separate anatomical domains. J Neurosci 22:183-92

Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, Jones T, Banati RB (2001) In-vivo measurement of activated microglia in dementia. Lancet. 358:461-7

Chang YIT, Jabs C, Sobel RA, Kuchroo VK, Sharpe AH. 1999 Studies in B7-deficient mice reveal a critical role for B7 costimulation in both induction and effector phases of experimental autoimmune encephalomyelitis. J Exp Med. 190:733-40

Cipriani B, Chen L, Hiromatsu K, Knowles H, Raine CS, Battistini L, Porcelli SA, Brosnan CF. 2003 Uregulation of group 1 CD1 antigen presenting molecules in guinea pigs with experimental autoimmune encephalomyelitis: an immunohistochemical study. Brain Pathol. Jan; 13(1):1-9.

Columba-Cabezas S, Serafini B, Ambrosini E, Aloisi F. 2003 Lymphoid chemokines CCL19 and CCL21 are expressed in the central nervous system during experimental autoimmune encephalomyelitis: implications for the maintenance of chronic neuroinflammation. Brain Pathol 13:38-51

Columba-Cabezas S, Serafini B, Ambrosini E, Sanchez M, Penna G, Adorini L, Aloisi F. 2002 Induction of macrophage-derived chemokine/CCL22 expression in experimental autoimmune encephalomyelitis and cultured microglia: implications for disease regulation. J Neuroimmunol. Sep;130(1-2): 10-21.

Cossmann PH, Eggli PS, Christ B, Kurz H (1997) Mesoderm-derived cells proliferate in the embryonic central nervous system: confocal microscopy and three-dimensional visualization. Histochem Cell Biol. 107:205-13.

Cross AH, Misko TP, Lin RF, Hickey WF, Trotter JL, Tilton RG. 1994 Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J Clin Invest. 93:2684-90.

Dangond F, Windhagen A, Groves CJ, Hafler DA 1997 Constitutive expression of costimulatory molecules by human microglia and its relevance to CNS autoimmunity. J Neuroimmunol. Sep;130(1-2):10-21.

De Groot CJ, Ruuls SR, Theeuwes JW, Dijkstra CD, Van der Valk P 1997 Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions. J Neuropathol Exp Neurol. 56:10-20
De Simone R, Giampaolo A, Giometto B, Gallo P, Levi G, Peschle C, Aloisi F. The costimulatory molecule B7 is expressed on human microglia in culture and in multiple sclerosis acute lesions. J Neuropathol Exp Neurol. 1995 Mar;54(2):175-87.

Deininger MH, Zhao Y, Schluesener HJ. 1999 CP-10, a chemotactic peptide, is expressed in lesions of experimental autoimmune encephalomyelitis, neuritis, uveitis and in C6 gliomas. J Neuroimmunol. 93(1-2):156-63.

Emerson MR, LeVine SM 2000 Heme oxygenase-1 and NADPH cytochrome P450 reductase expression in experimental allergic encephalomyelitis: an expanded view of the stress response. J Neurochem. 75:2555-62.

Espejo C, Carrasco J, Hidalgo J, Penkowa M, Garcia A, Saez-Torres I, Martinez-Caceres EM. 2001 Differential expression of metallothioneins in the CNS of mice with experimental autoimmune encephalomyelitis. Neuroscience. 105:1055-65.

Fischer HG, Reichmann G. 2001 Brain dendritic cells and macrophages/microglia in central nervous system inflammation. J Immunol. 166:2717-26.

Fleury SG, Croteau G, Sekaly RP (1991) CD4 and CD8 recognition of class II and class I molecules of the major histocompatibility complex. Semin Immunol 3:177-85.

Flugel A, Bradl M, Kreutzberg GW, Graeber MB. 2001 Transformation of donor-derived bone marrow precursors into host microglia during autoimmune CNS inflammation and during the retrograde response to axotomy. J Neurosci Res. Oct 1;66(1):74-82.

Ford AL, Foulcher E, Lemckert FA, Sedgwick JD 1996 Microglia induce CD4+ T lymphocyte final effector function and death. J Exp Med. 184(5):1737-45.

Ford AL, Goodsall AL, Hickey WF, Sedgwick JD. 1995 Normal adult ramified microglia separated from other central nervous system macrophages by flow cytometric sorting. Phenotypic differences defined and direct ex vivo antigen presentation to myelin basic protein-reactive CD4+ T cells compared. J Immunol May 1154(9):4309-21.

Gerritse K, Laman JD, Noelle RJ, Aruffo A, Ledbetter JA, Boersma WJ, Claassen E 1996 CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc Natl Acad Sci U S A. Mar 19;93(6):2499-504.

Geurts JJ, Wolswijk G, Bo L, Van Der Valk P, Polman CH, Troost D, Aronica E. 2003 Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis. Brain. Jun 4 [Epub ahead of print].

Girvin AM, Dal Canto MC, Miller SD (2002) CD40/CD40L interaction is essential for the induction of EAE in the absence of CD28-mediated co-stimulation. J Autoimmun. 18(2):83-94.

Gran B, Zhang GX, Yu S, Li J, Chen XH, Ventura ES, Kamoun M, Rostami A. 2002 IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination. J Immunol. 169(12):7104-10.

Hayes GM, Woodroofe MN, Cuzner ML. 1987 Microglia are the major cell type expressing MHC class II in human white matter. J Neurol Sci. 80:25-37.

Hickey WF, Kimura H. 1988 Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo. Science. 239:290-2.

Huang DR, Wang J, Kivisakk P, Rollins BJ, Ransohoff RM (2001) Absence of monocyte chemotactrant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis. J Exp Med. 193:713-26.

Huitinga I, Ruuls SR, Jung S, Van Rooijen N, Hartung HP, Dijkstra CD. 1995 Macrophages in T cell line-mediated, demyelinating, and chronic relapsing experimental autoimmune encephalomyelitis in Lewis rats. Clin Exp Immunol 100:344-51.
Hulkower K, Brosnan CF, Aquino DA, Cammer W, Kulshrestha S, Guida MP, Rapoport DA, Berman JW. 1993 Expression of CSF-1, c-fms, and MCP-1 in the central nervous system of rats with experimental allergic encephalomyelitis. J Immunol. 150:2525-33.

Jacobs CA, Baker PE, Roux ER, Picha KS, Toivola B, Waugh S, Kennedy MK. 1991 Experimental autoimmune encephalomyelitis is exacerbated by IL-1 alpha and suppressed by soluble IL-1 receptor. J Immunol. 146:2983-9.

Jahng AW, Maricic I, Pedersen B, Burdin N, Naidenko O, Kronenberg M, Koezuka Y, Kumar V. 2001 Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J Exp Med. 194:1789-99

Jander S, Pohl J, D'Urso D, Gillen C, Stoll G. 1998 Time course and cellular localization of interleukin-10 mRNA and protein expression in autoimmune inflammation of the rat central nervous system. Am J Pathol. 152:975-82

Jee Y, Yoon WK, Okura Y, Tanuma N, Matsumoto Y. 2002 Upregulation of monocyte chemotactic protein-1 and CC chemokine receptor 2 in the central nervous system is closely associated with relapse of autoimmune encephalomyelitis in Lewis rats. J Neuroimmunol. Jul; 128(1-2):49-57

Jiang Y, Salafranca MN, Adhikari S, Xia Y, Feng L, Sonntag MK, deFiebre CM, Pennell NA, Streit WJ, Harrison JK. 1998 Chemokine receptor expression in cultured glia and rat experimental allergic encephalomyelitis. J Neuroimmunol. 86:1-12

Jones RE, Mass M, Bourdette DN. 1999 Myelin basic protein-specific T lymphocytes induce chronic relapsing experimental autoimmune encephalomyelitis in lymphocyte-deficient (SCID) mice. J Neuroimmunol. Jan 1;93(1-2):92-101

Juedes AE, Hjelmstrom P, Bergman CM, Neil AL, Ruddle NH. 2000 Kinetics and cellular origin of cytokines in the central nervous system: insight into mechanisms of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis. J Immunol. 164:419-26

Juedes AE, Ruddle NH. 2001 Resident and infiltrating central nervous system APCs regulate the emergence and resolution of experimental autoimmune encephalomyelitis. J Immunol. Apr 15;166(8):5168-75.

Karpus WJ, Lukacs NW, McRae BL, Strieter RM, Kunkel SL, Miller SD. 1995 An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol. 155:5003-10

Kean RB, Spitsin SV, Mikheeva T, Scott GS, Hooper DC 2000 The peroxynitrite scavenger uric acid prevents inflammatory cell invasion into the central nervous system in experimental allergic encephalomyelitis through maintenance of blood-central nervous system barrier integrity. J Immunol. 165:6511-8.

Kiefer R, Schweitzer T, Jung S, Toyka KV, Hartung HP. 1998 Sequential expression of transforming growth factor-beta1 by T-cells, macrophages, and microglia in rat spinal cord during autoimmune inflammation. J Neuropathol Exp Neurol 57:385-95.

Klyushnenkova EN, Vanguri P 1997 Ia expression and antigen presentation by glia: strain and cell type-specific differences among rat astrocytes and microglia. J Neuroimmunol. 79(2):190-201

Konno H, Yamamoto T, Iwasaki Y, Saitoh T, Suzuki H, Terunuma H. 1989 Ia-expressing microglial cells in experimental allergic encephalomyelitis in rats. Acta Neuropathol (Berl) 77(5):472-9

Korner H, Lemckert FA, Chaudhri G, Etteldorf S, Sedgwick JD. 1997 Tumor necrosis factor blockade in actively induced experimental autoimmune encephalomyelitis prevents
clinical disease despite activated T cell infiltration to the central nervous system. Eur J Immunol. 27:1973-81

Kosel S, Egensperger R, Bise K, Arbogast S, Mehraein P, Graeber MB (1997) Long-lasting perivascular accumulation of major histocompatibility complex class II-positive lipophages in the spinal cord of stroke patients: possible relevance for the immune privilege of the brain. Acta Neuropathol (Berl). 94:532-8

Kuchroo VK, Das MP, Brown JA, Ranger AM, Zamvil SS, Sobel RA, Weiner HL, Nabavi N, Glimcher LH. 1995 B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell. 80:707-18

Kuhlmann T, Lingfeld G, Bitsch A, Schuchhardt J, Bruck W. 2002 Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain. 125:2202-12

Kurz H, Christ B (1998) Embryonic CNS macrophages and microglia do not stem from circulating, but from extravascular precursors. Glia 22:98-102

Laman JD, van Meurs M, Schellekens MM, de Boer M, Melchers B, Massacesi L, Lassmann H, Claassen E, Hart BA. 1998 Expression of accessory molecules and cytokines in acute EAE in marmoset monkeys (Callithrix jacchus). J Neuroimmunol. Jun 1;86(1):30-45

Larsson M, Fonteneau JF, Bhardwaj N (2001) Dendritic cells resurrect antigens from dead cells. Trends Immunol 22:141-8

Leonard JP, Waldburger KE, Goldman SJ. 1995 Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med. 181:381-6

LeVine SM. 1997 Iron deposits in multiple sclerosis and Alzheimer's disease brains. Brain Res. Jun 20;760(1-2):298-303

Li H, Cuzner ML, Newcombe J 1996 Microglia-derived macrophages in early multiple sclerosis plaques. Neuropathol Appl Neurobiol. 22(3):207-15

Lider O, Miller A, Miron S, Hershkoviz R, Weiner HL, Zhang XM, Heber-Katz E (1991) Nonencephalitogenic CD4-CD8- V alpha 2V beta 8.2+ anti-myelin basic protein rat T lymphocytes inhibit disease induction. J Immunol. 1991 Aug 15;147(4):1208-13.

Linehan SA, Martinez-Pomares L, Stahl PD, Gordon S (1999) Mannose receptor and its putative ligands in normal murine lymphoid and nonlymphoid organs: In situ expression of mannose receptor by selected macrophages, endothelial cells, perivascular microglia, and mesangial cells, but not dendritic cells. J Exp Med 189:1961-72

Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapura J, Slavin AJ, Old L, Bernard CC. 1998 TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med. 4:78-83

Liu Y, Zhu B, Luo L, Li P, Paty DW, Cynader MS. 2001 Heme oxygenase-1 plays an important protective role in experimental autoimmune encephalomyelitis. Neuroreport. 12:1841-5

Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. 2000 Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 47:707-17

Marusic S, Miyashiro JS, Douhan J 3rd, Konz RF, Xuan D, Pelker JW, Ling V, Leonard JP, Jacobs KA. 2002 Local delivery of granulocyte macrophage colony-stimulating factor by retrovirally transduced antigen-specific T cells leads to severe, chronic experimental autoimmune encephalomyelitis in mice. Neurosci Lett. 332:185-9.
A7. Role of Microglia and Macrophages in EAE

Matejuk A, Dwyer J, Ito A, Bruender Z, Vandenbark AA, Offner H. 2002 Effects of cytokine deficiency on chemokine expression in CNS of mice with EAE. J Neurosci Res. 67(5):680-8

Matsumoto Y, Ohmori K, Fujiwara M. 1992 Microglial and astroglial reactions to inflammatory lesions of experimental autoimmune encephalomyelitis in the rat central nervous system. J Neuroimmunol Mar 37(1-2):23-33

McCombe PA, de Jersey J, Pender MP. 1994 Inflammatory cells, microglia and MHC class II antigen-positive cells in the spinal cord of Lewis rats with acute and chronic relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 51(2):153-67

McCombe PA, Fordyce BW, de Jersey J, Yoong G, Pender MP. 1992 Expression of CD45RC and Ia antigen in the spinal cord in acute experimental allergic encephalomyelitis: an immunocytochemical and flow cytometric study. J Neurol Sci Dec 113(2):177-86

McGeer PL, Itagaki S, McGeer EG. 1988 Expression of the histocompatibility glycoprotein HLA-DR in neurological disease. Acta Neuropathol (Berl). 76(6):550-7

McQualter JL, Darwiche R, Ewing C, Onuki M, Kay TW, Hamilton JA, Reid HH, Bernard CC. 2001 Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J Exp Med. 194:873-82

Miceli MC, Pames JR (1991) The roles of CD4 and CD8 in T cell activation. Semin Immunol 3:133-41

Mitrovic B, Parkinson J, Merrill JE 1996 An in Vitro Model of Oligodendrocyte Destruction by Nitric Oxide and Its Relevance to Multiple Sclerosis. Methods 10:501-13

Miyagishi R, Kikuchi S, Takayama C, Inoue Y, Tashiro K. 1997 Identification of cell types producing RANTES, MIP-1 alpha and MIP-1 beta in rat experimental autoimmune encephalomyelitis by in situ hybridization. J Neuroimmunol. 77:17-26

Miyamoto K, Miyake S, Yamamura T. 2001 A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature. 413:531-4

Muller-Ladner U, Jones JL, Wetsel RA, Gay S, Raine CS, Barnum SR 1996 Enhanced expression of chemotactic receptors in multiple sclerosis lesions. J Neurol Sci. Dec;144(1-2):135-41

Murphy CA, Hoek RM, Wiekowski MT, Lira SA, Sedgwick JD. 2002. Interactions between hematopoietically derived TNF and central nervous system-resident glial chemokines underlie initiation of autoimmune inflammation in the brain. J. Immunol 169:7054-62

Nagra RM, Becher B, Tourtellotte WW, Antel JP, Gold D, Paladino T, Smith RA, Nelson JR, Reynolds WP. 1997 Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. J Neuroimmunol. 78:97-107

Navascues J, Moujahid A, Almendros A, Marin-Teva JL, Cuadros MA (1995) Origin of microglia in the quail retina: central-to-peripheral and vitreal-to-scleral migration of microglial precursors during development. J Comp Neurol. 354:209-28.

Nedergaard M (1994) Direct signaling from astrocytes to neurons in cultures of mammalian brain cells. Science Mar 25;263(5154):1768-71

Nguyen KB, McCombe PA, Pender MP. 1994 Macrophage apoptosis in the central nervous system in experimental autoimmune encephalomyelitis. J Autoimmun 7(2):145-52

O’Brien NC, Charlton B, Cowden WB, Willenberg DO. 2001 Inhibition of nitric oxide synthase initiates relapsing remitting experimental autoimmune encephalomyelitis in rats, yet nitric oxide appears to be essential for clinical expression of disease. J Immunol. 167:5904-12

Ohmori K, Hong Y, Fujiwara M, Matsumoto Y. 1992 In situ demonstration of proliferating cells in the rat central nervous system during experimental autoimmune encephalomyelitis. Evidence suggesting that most infiltrating T cells do not proliferate in the target organ. Lab Invest Jan 66(1):54-62
128

Chapter A7

Okuda Y, Sakoda S, Fujimura H, Yanagihara T. 1998 Aminoguanidine, a selective inhibitor of the inducible nitric oxide synthase, has different effects on experimental allergic encephalomyelitis in the induction and progression phase. J Neuroimmunol. 81:201-10

Oleszak EL, Katsetos CD, Kuzmak J, Varadhachary A. 1997 Inducible nitric oxide synthase in Theiler's murine encephalomyelitis virus infection. J Virol. 71:3282-83

Ouallet J, Baumann N, Marie Y, Villarroya H. 1999 Fas system up-regulation in experimental autoimmune encephalomyelitis. J Neurol Sci. 170:96-104.

Owens T, Tran E, Hassan-Zahraee M, Krakowski M (1998) Immune cell entry to the CNS--a focus for immunoregulation of EAE. Res Immunol 149:781-9

Pagenstecher A, Lassmann S, Carson MJ, Kincaid CL, Stalder AK, Campbell IL. 2000 Astrocyte-targeted expression of IL-12 induces active cellular immune responses in the central nervous system and modulates experimental allergic encephalomyelitis. J Immunol. 164(9):4481-92.

Pan Y, Zhou H, Dolich S, Deeds J, Gonzalez JA, Vath J, Gosselin M, Ma J, Dussault B, Woolf E, Alperin G, Culpepper J, Gutierrez-Ramos JC, Gearing D 1997 Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 387:611-7

Penkowa M, Espejo C, Martinez-Caceres EM, Poulsen CB, Montalban X, Hidalgo J, 2001 Altered inflammatory response and increased neurodegeneration in metallothionein I-II deficient mice during experimental autoimmune encephalomyelitis. J Neuroimmunol. 119:248-60

Polfliet MM, van de Veerdonk F, Dopp EA, van Kesteren-Hendrikx EM, van Rooijen N, Dijkstra CD, van den Berg TK 2002 The role of perivascular and meningeal macrophages in experimental allergic encephalomyelitis. J Neuroimmunol 122:1-8

Priller J, Flugel A, Wehner T, Boentert M, Haas CA, Prinz M, Fernandez-Klett F, Prass K, Bechmann I, de Boer BA, Frotscher M, Kreutzberg GW, Persons DA, Dirnagl U. (2001) Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat Med 7:1356-61

Qi X, Guy J, Nick H, Valentine J, Rao N. 1997 Increase of manganese superoxide dismutase, but not of Cu/Zn-SOD, in experimental optic neuritis. Invest Ophthalmol Vis Sci. 38:1203-12

Raivich G, Bohatschek M, Kloss CU, Werner A, Jones LL, Kreutzberg GW. 1999. Neuroligial activation repertoire in the injured brain: graded response, molecular mechanisms and cues to physiological function. Brain Res Rev 30:77-105

Reimann J, Bohm W, Schirmbeck R (1994) Alternative processing pathways for MHC class I-restricted epitope presentation to CD8+ cytotoxic T lymphocytes. Biol Chem Hoppe Seyler 375:731-6

Renno T, Krakowski M, Piccirillo C, Lin JY, Owens T. 1995 TNF-alpha expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis. Regulation by Th1 cytokines. J Immunol Jan 15 154(2):944-53

Rinner WA, Bauer J, Schmidts M, Lassmann H, Hickey WF. 1995 Resident microglia and hematogenous macrophages as phagocytes in adoptively transferred experimental autoimmune encephalomyelitis: an investigation using rat radiation bone marrow chimeras. Glia 14:257-66

Rott O, Fleischer B, Cash E (1994) Interleukin-10 prevents experimental allergic encephalomyelitis in rats. Eur J Immunol. 24:1434-40
A7. Role of Microglia and Macrophages in EAE

Rottman JB, Slavin AJ, Silva R, Weiner HL, Hancock WW. 2000 Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent. Eur J Immunol. 30:2372-7

Ruuls SR, Bauer J, Sontrop K, Huitinga I, 't Hart BA, Dijkstra CD. 1995 Reactive oxygen species are involved in the pathogenesis of experimental allergic encephalomyelitis in Lewis rats. J Neuroimmunol 56:207-17

Ruuls SR, Van Der Linden S, Sontrop K, Huitinga I, Dijkstra CD 1996 Aggravation of experimental allergic encephalomyelitis (EAE) by administration of nitric oxide (NO) synthase inhibitors. Clin Exp Immunol. 103:467-74

Schiffenbauer J, Streit WJ, Butfiloski E, LaBow M, Edwards C 3rd, Moldawer LL. 2000 The induction of EAE is only partially dependent on TNF receptor signaling but requires the IL-1 type I receptor. Clin Immunol. 95:117-23

Schluesener HJ, Seid K, Kretzschmar J, Meyermann R 1996 Leukocyte chemotactic factor, a natural ligand to CD4, is expressed by lymphocytes and microglial cells of the MS plaque. J Neurosci Res 44(6):606-11

Schluesener HJ, Seid K, Zhao Y, Meyermann R. 1997 Localization of endothelial-monocyte-activating polypeptide II (EMAP II), a novel proinflammatory cytokine, to lesions of experimental autoimmune encephalomyelitis, neuritis and uveitis: expression by monocytes and activated microglial cells. Glia. Aug;20(4):365-72

Schluesener HJ, Seid K. 2000 Heme oxygenase-1 in lesions of rat experimental autoimmune encephalomyelitis and neuritis. J Neuroimmunol. 110:114-20

Schonrock LM, Kuhlmann T, Adler S, Bitsch A, Bruck W. 1998 Identification of glial cell proliferation in early multiple sclerosis lesions. Neuropathol Appl Neurobiol. 24(4):320-30

Sedgwick JD, Schwender S, Gregersen R, Dorries R, ter Meulen V 1993 Resident macrophages (ramified microglia) of the adult brown Norway rat central nervous system are constitutively major histocompatibility complex class II positive. J Exp Med. 177(4):1145-52.

Selkjem K, Raine CS, Cross AH. 1991 Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol. 30:694-700

Simpson J, Rezaie P, Newcombe J, Cuzner ML, Male D, Woodrofe MN. 2000 Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. J Neuroimmunol. 108(1-2):192-200

Smith T, Schmied M, Hewson AK, Lassmann H, Cuzner ML. 1996 Apoptosis of T cells and macrophages in the central nervous system of intact and adrenalectomized Lewis rats during experimental allergic encephalomyelitis. J Autoimmun. Apr;9(2):167-74

Sorensen TL, Tani M, Jensen J, Pierce V, Lucchineti C, Folck VA, Qin S, Rottman J, Sellebjerg F, Strieter RM, Frederiksen JL, Ransohoff RM. 1999 Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest. 103:807-15

Stalder AK, Carson MJ, Pagenstecher A, Asensio VC, Kincaid C, Benedict M, Powell HC, Masliah E, Campbell IL. 1998 Late-onset chronic inflammatory encephalopathy in immune-competent and severe combined immune-deficient (SCID) mice with astrocyte-targeted expression of tumor necrosis factor. Am J Pathol 153:767-83

Stephenson DT, Schober DA, Smalstig EB, Mincy RE, Gehlert DR, Clemens JA (1995) Peripheral benzodiazepine receptors are colocalized with activated microglia following transient global forebrain ischemia in the rat. J Neurosci. 15:5263-74.

Stevens DB, Gould KE, Swanborg RH. 1994 Transforming growth factor-beta 1 inhibits tumor necrosis factor-alpha/lymphotoxin production and adoptive transfer of disease by effector cells of autoimmune encephalomyelitis. J Neuroimmunol. 51:77-83
Stoll G, Jander S (1999) The role of microglia and macrophages in the pathophysiology of the CNS. Prog Neurobiol. 58:233-47

Storch MK, Fischer-Colbrie R, Smith T, Rinner WA, Hickey WF, Cuzner ML, Winkler H, Lassmann H 1996 Co-localization of secretoneurin immunoreactivity and macrophage infiltration in the lesions of experimental autoimmune encephalomyelitis. Neuroscience. Apr;71(3):885-93

Streit WJ, Graeber MB, Kreutzberg GW (1989) Expression of Ia antigen on perivascular and microglial cells after sublethal and lethal motor neuron injury. Exp Neurol 105:115-26

Subramanian S, Bourdette DN, Corless C, Vandenbark AA, Offner H, Jones RE. 2001 T lymphocytes promote the development of bone marrow-derived APC in the central nervous system. J Immunol. 166(1):370-6

Sugita M, Moody DB, Jackman RM, Grant EP, Rosat JP, Behar SM, Peters PJ, Porcelli SA, Brenner MB. 1998 CD1--a new paradigm for antigen presentation and T cell activation. Clin Immunol Immunopathol. 87:8-14

Sun D, Whitaker JN, Huang Z, Liu D, Coleclough C, Wekerle H, Raine CS. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol. 2001 Jun 15;166(12):7579-87

Suter T, Malipiero U, Otten L, Ludewig B, Muelethaler-Mottet A, Mach B, Reith W, Fontana A. 2000 Dendritic cells and differential usage of the MHC class II transactivator promoters in the central nervous system in experimental autoimmune encephalitis. Eur J Immunol 30(3):794-802

Suzuki M, Raisman G (1992) The glial framework of central white matter tracts: segmented rows of contiguous interfascicular oligodendrocytes and solitary astrocytes give rise to a continuous meshwork of transverse and longitudinal processes in the adult rat fimbria. Glia 6:222-35

Takahashi JL, Giuliani F, Power C, Imai Y, Yong VW. 2003 Interleukin-1beta promotes oligodendrocyte death through glutamate excitotoxicity. Ann Neurol. 53:588-95

Taupin V, Renno T, Bourbonniere L, Peterson AC, Rodriguez M, Owens T 1997 Increased severity of experimental autoimmune encephalomyelitis, chronic macrophage/microglial reactivity, and demyelination in transgenic mice producing tumor necrosis factor-alpha in the central nervous system. Eur J Immunol. 27:905-13

Tran EH, Hardin-Pouzet H, Verge G, Owens T. 1997 Astrocytes and microglia express inducible nitric oxide synthase in mice with experimental allergic encephalomyelitis. J Neuroimmunol. 74:1-9

Tran EH, Hoekstra K, van Rooijen N, Dijkstra CD, Owens T. 1998 Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice. J Immunol 161:3767-75

Trebst C, Sorensen TL, Kivisakk P, Cathcart MK, Hesselgesser J, Horuk R, Sellebjerg F, Lassmann H, Ransohoff RM. 2001 CCR1+/CCR5+ mononuclear phagocytes accumulate in the central nervous system of patients with multiple sclerosis. Am J Pathol 159:1701-10

Trebst C, Staugaitis SM, Kivisakk P, Mahad D, Cathcart MK, Tucky B, Wei T, Rani MR, Horuk R, Aldape KD, Pardo CA, Lucchinetti CF, Lassmann H, Ransohoff RM. 2003 CC chemokine receptor 8 in the central nervous system is associated with phagocytic macrophages. Am J Pathol. 162:427-38
Van Dam AM, Bauer J, Man-A-Hing WK, Marquette C, Tilders FJ, Berkenbosch F: 1995 Appearance of inducible nitric oxide synthase in the rat central nervous system after rabies virus infection and during experimental allergic encephalomyelitis but not after peripheral administration of endotoxin. J Neurosci Res. Feb 1;40(2):251-60

Waldburger KE, Hastings RC, Schaub RG, Goldman SJ, Leonard JP 1996 Adoptive transfer of experimental allergic encephalomyelitis after in vitro treatment with recombinant murine interleukin-12. Preferential expansion of interferon-gamma-producing cells and increased expression of macrophage-associated inducible nitric oxide synthase as immunomodulatory mechanisms. Am J Pathol. Feb;148(2):375-82

Walther M, Popratiloff A, Lachnit N, Hofmann N, Streppel M, Guntinas-Lichius O, Neiss WF, Angelov DN. (2001) Exogenous antigen containing perivascular phagocytes induce a non-encephalitogenic extravasation of primed lymphocytes. J Neuroimmunol 117:30-42

Weinberg AD, Wegmann KW, Funatake C, Whitham RH. 1999 Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol 162(3):1818-26

Werner K, Bitsch A, Bunkowski S, Hemmerlein B, Bruck W. 2002 The relative number of macrophages/microglia expressing macrophage colony-stimulating factor and its receptor decreases in multiple sclerosis lesions. Glia 40:121-9

Willenborg DO, Fordham SA, Staykova MA, Ramshaw IA, Cowden WB. 1999 IFN-gamma is critical to the control of murine autoimmune encephalomyelitis and regulates both in the periphery and in the target tissue: a possible role for nitric oxide. J Immunol. 163:5278-86

Williams K, Ulvestad E, Antel JP. B7/BB-1 antigen expression on adult human microglia studied in vitro and in situ. Eur J Immunol. 1994 Dec;24(12):3031-7

Xue S, Sun N, Van Rooijen N, Perlman S. 1999 Depletion of blood-borne macrophages does not reduce demyelination in mice infected with a neurotropic coronavirus. J Virol 73:6327-34

Zhu B, Luo L, Chen Y, Paty DW, Cynader MS. 2002 Intrathecal Fas ligand infusion strengthens immunoprivilege of central nervous system and suppresses experimental autoimmune encephalomyelitis. J Immunol. 169:1561-9

Zinkernagel RM, Doherty PC (1997) The discovery of MHC restriction. Immunol Today 18:14-7